A study of growth, development and maturation in adolescents with atopic dermatitis who receive upadacitinib

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/106181
• EU PAS number:
  EUPAS106180
• Study ID:
  106181
• Official title and acronym:
  A study of growth, development and maturation in adolescents with atopic dermatitis who receive upadacitinib
• DARWIN EU® study:
  No
• Study countries:
  Canada

  France

  Germany

  Latvia

  Spain

  Türkiye

  United States
• Study description:
  This will be an observational, prospective cohort study of adolescents who receive upadacitinib or biologic or other non-biologic, non-JAKi systemic therapies approved for the treatment of moderate to severe AD at the time of registry enrollment.
• Study status:
  Ongoing

Study timelines

Date when funding contract was signed

Actual: 22/03/2021

Study start date

Planned: 15/11/2023

Actual: 20/12/2023

Date of final study report

Planned: 31/12/2033

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AbbVie

Study protocol

Initial protocol

P21-824_Protocol_Abstract_Redacted

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

P21-824